GPER functions as a tumor suppressor in triple-negative breast cancer cells (Q39022382)

8 September 2017

title

GPER functions as a tumor suppressor in triple-negative breast cancer cells (English)

1 reference

triple-negative breast cancer

8 September 2017

main subject

1 reference

inferred from title

author

Ana Claudia Zenclussen

object named as

Ana Claudia Zenclussen

5

0 references

Zoya Ignatova

object named as

Zoya Ignatova

6

0 references

author name string

Christine Weißenborn

1

1 reference

8 September 2017

Tanja Ignatov

2

1 reference

8 September 2017

Hans-Joachim Ochel

3

1 reference

8 September 2017

Serban Dan Costa

4

1 reference

8 September 2017

Atanas Ignatov

7

1 reference

8 September 2017

publication date

20 February 2014

1 reference

Journal of Cancer Research and Clinical Oncology

8 September 2017

published in

1 reference

8 September 2017

volume

140

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

713-723

1 reference

G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Virtual and biomolecular screening converge on a selective agonist for GPR30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

In vivo effects of a GPR30 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

G-protein-coupled receptors and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

P53 and radiation responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Histone H3 phosphorylation and cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

APC promoter hypermethylation is an early event in endometrial tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Role of GPR30 in endometrial pathology after tamoxifen for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

GPER-1 acts as a tumor suppressor in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

GPER-1 expression decreases during breast cancer tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

MethPrimer: designing primers for methylation PCRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Mutant p53 mediates survival of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

GPR30 predicts poor survival for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Functional mechanisms for human tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

An essential role for p73 in regulating mitotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

The correlation between GPR30 and clinicopathologic variables in breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1620-8

Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.

21 January 2018

1 reference

12 December 2020

The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population

1 reference

12 December 2020

The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner.

1 reference

12 December 2020

P16 alterations increase the metastatic potential of endometrial carcinoma

1 reference

12 December 2020

Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression

1 reference

12 December 2020

Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.

1 reference

12 December 2020

Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.

1 reference

12 December 2020

The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle

1 reference

12 December 2020

A gene hypermethylation profile of human cancer

1 reference

12 December 2020

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

1 reference

12 December 2020

Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis

1 reference

12 December 2020

Participation of p53 protein in the cellular response to DNA damage

1 reference

12 December 2020

GPR30: a novel indicator of poor survival for endometrial carcinoma

1 reference

12 December 2020

10.1007/S00432-014-1620-8

Identifiers

DOI

1 reference

8 September 2017

1 reference